Celgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound for the treatment of cancer. Under the agreement, Celgene will pay $35M for further R&D, and will retain the option to make an equity investment in VentiRx or aquire the company.